QURE uniQure N.V. Insider Trading

CEO Matthew C Kapusta sold 21,082 shares (21.1K) at $45.16 avg for $952,051.26; part of scheduled 10b5-1 plan; held 519.2K shares post-trade.

Matthew C Kapusta, CEO and Managing Director, executed 3 separate sales totaling 21,082 shares for $952,051.26 on 2026-07-02 under a pre-arranged 10b5-1 trading plan adopted 2025-10-05. The sales occurred at prices ranging from $44.43 to $45.89, with a blended average of $45.16, against a current price of $41.41 (42.1% below the 52-week high of $71.50). His post-transaction holdings of 519.2K shares represent a 3.9% reduction from pre-transaction holdings of 540.3K shares. Notably, this is part of a recent pattern: Kapusta has executed 5 sells at this ticker within the prior 8 calendar days (2026-06-17 through 2026-06-25), all scheduled under the 10b5-1 plan. Context: uniQure reported negative annual revenue growth of -40.6%, a most-recent quarter revenue of $3.6M, and full-year net income of -$53.5M (unprofitable). The scheduled nature of these transactions (governed by the 10b5-1 plan) removes discretionary timing from the interpretation.

Chief Medical Officer Walid Abi-Saab sold 30,000 shares for $1,392,600 via scheduled 10b5-1 plan; stock down -41.5% from 52-week high.

Walid Abi-Saab, Chief Medical Officer at uniQure N.V., executed 2 separate sales totaling 30,000 shares for $1,392,600.00 on 2026-06-30 under a pre-arranged 10b5-1 trading plan adopted on 2025-09-26. Post-transaction, he holds 148,235 shares of non-derivative stock, a reduction of 16.8% versus his pre-transaction position of 178,235 shares. The company trades at $41.81, which is -41.5% from its 52-week high of $71.50, while the blended sale price was $46.42. uniQure faces significant operational headwinds: latest quarterly revenue was $3,562,000.00, annual revenue growth was -40.6%, and full-year net income was negative at $-53,535,000.00. The sale is structured as a scheduled, non-discretionary transaction under 10b5-1 framework, not a discretionary market decision. Abi-Saab retains derivative holdings of 50,500 shares through stock options, preserving an ongoing equity interest in the company.

CEO Kapusta sells 35,412 shares at avg $50.02 under 10b5-1 plan; holds 519,227 shares post-sale plus 120,440 in options.

Matthew C Kapusta, CEO, executed 2 separate sales totaling 35,412 shares for $1,771,174.32 on 2026-06-24 and 2026-06-25 under a pre-arranged 10b5-1 trading plan adopted 2025-10-05. His non-derivative holdings fell 6.4% from 554,639 to 519,227 shares, while he retains 120,440 shares in stock options (Table II). The sales occurred at $50.02 blended average; the stock now trades at $47.51, 33.6% below its 52-week high. Historically, Kapusta's prior 5 trades at this ticker (all September 2025 sales) showed 30-day gains averaging between 35.3% and 54.1%, followed by 90-day losses ranging from -38.9% to -46.4%, a pattern of initial strength reversing to decline. The underlying company is unprofitable (net loss $-53,535,000.00 last quarter) with sharply declining revenue (-40.6% YoY), creating structural headwinds independent of execution timing. This is a scheduled divestiture consistent with prior tax or liquidity planning, not a discretionary market-timing signal.

CEO Matthew C Kapusta executes 8 scheduled sales of 206,100 shares for $9,371,611.75 under 10b5-1 plan; retains 521,795 shares plus 99,788 derivative holdings.

Matthew C Kapusta, CEO and Managing Director of uniQure N.V., executed 8 separate sales totaling 206,100 shares for $9,371,611.75 on 2026-06-17 and 2026-06-18, with a blended average price of $45.47. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-10-05 and represents a scheduled, non-discretionary reduction of 28.3% from his pre-transaction holdings of 727,895 shares. His prior sales at QURE (5 trades on 2025-09-24) have shown consistent 30-day gains (ranging from +35.3% to +54.1%) followed by negative 90-day returns (ranging from -38.9% to -46.4%), a pattern that reflects the stock's recent volatility: current price is $46.29, up 87.5% over 30 days and +187.7% over 90 days but down 35.3% from its 52-week high of $71.50. The company is unprofitable (full-year net income was negative) with annual revenue growth of -40.6% and quarterly revenue of $3,562,000.00 against a net loss of $53,535,000.00, creating a fundamental backdrop of operational challenge that warrants investor attention alongside the scheduled equity reduction.

CMO Walid Abi-Saab exercises shares and sells 45,000 shares for ~$1.1M net, reducing stake by 10.5% as stock trades well below 52-week highs.

Walid Abi-Saab, Chief Medical Officer, exercised 25,000 shares and immediately sold 45,000 shares on the same day for a combined ~$1.1M, reducing his holdings by roughly one-tenth. This is his 6th and 7th open-market sale in the past three years—his pattern is consistently disposing shares when opportunities arise, with no open-market purchases in the same window. The sales themselves are not dramatic given the company's financial picture: uniQure is unprofitable with recent revenue declining sharply and net losses continuing to mount. The stock trades significantly below its 52-week high, having declined from the upper range over recent months. While a single executive selling during a period of financial strain is not unusual, the pattern of consistent dispositions—particularly a c-suite sale exceeding $1.1M in a single trading session—warrants attention to whether other officers or directors are also reducing exposure or whether this reflects normal equity management by a long-tenured medical officer with accumulated shares from compensation.

Director Kaye Jack sells 38,810 shares for $1.2M under pre-arranged 10b5-1 plan; post-transaction holdings 20,439 shares.

Kaye Jack, a Director at uniQure N.V., executed 3 separate sales totaling 38,810 shares for $1,177,517.30 on 2025-11-04 at prices ranging from $30.33 to $30.36, with a blended average of $30.34. This transaction was executed pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-06-16, meaning the sales were scheduled rather than discretionary. The sales reduced his holdings from 59,249 shares to 20,439 shares, representing a reduction of 65.5% of pre-transaction holdings. Since this activity is governed by a pre-planned trading schedule, it should be evaluated as scheduled portfolio activity rather than as a signal of current market conviction or timing-driven decision-making.

uniQure CFO Christian Klemt sold 18,000 shares across 2 transactions for $945,120.00 via 10b5-1 plan

Christian Klemt, uniQure's CFO, executed 2 separate sales totaling 18,000 shares for $945,120.00 under a pre-arranged 10b5-1 trading plan adopted on 2025-01-13. The first sale on 2025-09-24 was 3,000 shares at $40.04, followed by 15,000 shares at $55.00 on 2025-09-26, reflecting a blended average price of $52.51. His post-transaction holdings stand at 217,730 shares, a reduction of 7.6% from pre-transaction levels. As this activity is scheduled under a 10b5-1 plan rather than discretionary, it represents a pre-committed trading calendar and does not signal tactical conviction or concern regarding the stock's near-term direction.

uniQure CEO Matthew C Kapusta sold 226,316 shares for $9,382,472.66 under pre-arranged 10b5-1 plan executed on 2025-09-24

Matthew C Kapusta, CEO and Managing Director of uniQure N.V., executed 5 separate sales totaling 226,316 shares for $9,382,472.66 on 2025-09-24, with prices ranging from $39.59 to $45.10 and a blended average of $41.46. This transaction reduced his holdings from 877,770 shares to 651,454 shares, a decline of 25.8%. The sales were executed pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-01-28, meaning the transaction was scheduled and not discretionary in timing. As a programmed divestiture under Rule 10b5-1, this sale reflects a contractual commitment established months prior rather than a response to current market conditions or company developments.

CEO Kapusta Matthew C sold 100,000 shares of QURE at $15.03 on 2024-12-10 via pre-arranged 10b5-1 plan

Matthew C Kapusta, CEO and Managing Director of uniQure N.V., sold 100,000 shares (100.0K shares) at $15.03 on 2024-12-10, reducing holdings from 697,915 shares (697.9K shares) to 597,915 shares (597.9K shares), a reduction of -14.3% of pre-transaction holdings valued at $1,503,000.00. This transaction was executed pursuant to a pre-arranged 10b5-1 trading plan adopted on 2024-08-12, making it a scheduled and non-discretionary sale rather than a response to current market conditions. As a scheduled disposition under Rule 10b5-1, the timing reflects a predetermined arrangement rather than any contemporaneous market judgment or confidence signal.